These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 26351817)

  • 1. Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation.
    Drossaerts J; Vrijens D; Leue C; Schilders I; Van Kerrebroeck P; van Koeveringe G
    Neurourol Urodyn; 2016 Nov; 35(8):1011-1016. PubMed ID: 26351817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Affective symptoms and quality of life in patients with voiding or storage dysfunction: Results before and after sacral neuromodulation: A prospective follow-up study.
    Jairam R; Drossaerts J; Vrijens D; Leue C; van Kerrebroeck P; van Koeveringe G
    Neurourol Urodyn; 2018 Jun; 37(5):1801-1808. PubMed ID: 29504634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of urodynamic tools to guide patient selection in sacral neuromodulation.
    Drossaerts J; Rademakers K; van Koeveringe G; Van Kerrebroeck P
    World J Urol; 2015 Nov; 33(11):1889-95. PubMed ID: 25680936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
    Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
    Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychological and psychiatric factors as predictors for success in sacral neuromodulation treatment.
    Marcelissen TA; Leong RK; Nieman FH; van Lankveld JJ; van Kerrebroeck PE; de Wachter SG
    BJU Int; 2011 Dec; 108(11):1834-8. PubMed ID: 21810157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy.
    Leong RK; De Wachter SG; Nieman FH; de Bie RA; van Kerrebroeck PE
    Neurourol Urodyn; 2011 Sep; 30(7):1249-52. PubMed ID: 21404317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacral neuromodulation treatment for urinary voiding dysfunctions: results of treatment with the largest single-center series in a tertiary referral center in Turkey.
    Kütükoğlu MU; Altuntaş T; Şahin B; Onur AR
    Turk J Med Sci; 2023 Feb; 53(1):206-210. PubMed ID: 36945940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal Lead Positioning in Sacral Neuromodulation: Which Factors Are Related to Treatment Outcome?
    Jairam R; Marcelissen T; van Koeveringe G; van Kerrebroeck P
    Neuromodulation; 2017 Dec; 20(8):830-835. PubMed ID: 28877395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Duration of Complaints on Successful Outcome of Sacral Neuromodulation.
    Jairam R; Drossaerts J; van Koeveringe G; van Kerrebroeck P
    Urol Int; 2017; 99(1):51-55. PubMed ID: 28478446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1-9 V) during Stage 1 sacral neuromodulation.
    Marinkovic SP; Ford JC
    BJU Int; 2018 Sep; 122(3):472-479. PubMed ID: 29637712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
    Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
    Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of sacral neuromodulation treatment success in men with impaired bladder emptying-time for a new diagnostic approach.
    Rademakers KL; Drossaerts JM; van Kerrebroeck PE; Oelke M; van Koeveringe GA
    Neurourol Urodyn; 2017 Mar; 36(3):808-810. PubMed ID: 27062496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Value of Ambulatory Urodynamics in the Evaluation of Treatment Effect of Sacral Neuromodulation.
    Drossaerts J; Rademakers KLJ; Rahnama'i SM; Marcelissen T; Van Kerrebroeck P; van Koeveringe G
    Urol Int; 2019; 102(3):299-305. PubMed ID: 30612126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of sacral neuromodulation on pudendal nerve function and female sexual function.
    Parnell BA; Howard JF; Geller EJ
    Neurourol Urodyn; 2015 Jun; 34(5):456-60. PubMed ID: 24615871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study.
    Lee KS; Yoo TK; Liao L; Wang J; Chuang YC; Liu SP; Chu R; Sumarsono B
    BMC Urol; 2017 Nov; 17(1):108. PubMed ID: 29162085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged percutaneous SNM testing does not cause infection-related explanation.
    Amend B; Bedke J; Khalil M; Stenzl A; Sievert KD
    BJU Int; 2013 Mar; 111(3):485-91. PubMed ID: 22738331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacral Neuromodulation with the InterStim™ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
    Chartier-Kastler E; Le Normand L; Ruffion A; Dargent F; Braguet R; Saussine C; Tanneau Y; Graziana JP; Ragni E; Rabut B; Rousseau T; Biardeau X; Gamé X; Pierrevelcin J; Brassart E; Fourmarier M; Stoica G; Berrogain N; Yaghi N; Pecoux F; Capon G; Ferchaud J; Peyrat L; Bryckaert PE; Karsenty G; Melotti A; Abouihia A; Keller DUJ; Cornu JN
    Eur Urol Focus; 2021 Nov; 7(6):1430-1437. PubMed ID: 32907782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes in a contemporary cohort undergoing sacral neuromodulation using optimized lead placement technique.
    Adelstein SA; Lee W; Gioia K; Moskowitz D; Stamnes K; Lucioni A; Kobashi KC; Lee UJ
    Neurourol Urodyn; 2019 Aug; 38(6):1595-1601. PubMed ID: 31044466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
    Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
    Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.